SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-006250
Filing Date
2023-03-13
Accepted
2023-03-13 06:25:13
Documents
13
Period of Report
2023-03-13
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K zvra20230311_8k.htm   iXBRL 8-K 29520
  Complete submission text file 0001437749-23-006250.txt   165133

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA zvra-20230313.xsd EX-101.SCH 3602
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE zvra-20230313_def.xml EX-101.DEF 11920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE zvra-20230313_lab.xml EX-101.LAB 15967
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zvra-20230313_pre.xml EX-101.PRE 12131
7 EXTRACTED XBRL INSTANCE DOCUMENT zvra20230311_8k_htm.xml XML 2661
Mailing Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747
Business Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416
ZEVRA THERAPEUTICS, INC. (Filer) CIK: 0001434647 (see all company filings)

IRS No.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36913 | Film No.: 23725619
SIC: 2834 Pharmaceutical Preparations